The MPP and ICAP at Columbia University signed a Memorandum of Understanding in May 2017 outlining a framework of collaboration to improve access to treatment for people living with HIV. The two organisations will work together to facilitate market introduction and uptake of jointly identified priority medicines for the prevention and treatment of HIV in low- and middle-income countries (LMICs), particularly where ICAP operates. The MPP and ICAP have also agreed to explore opportunities for collaboration in tuberculosis, including TB/HIV co-infection. Founded in 2003 at Columbia University’s Mailman School of Public Health, ICAP is one of the largest U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) implementing partners. To date, ICAP has supported programs and research to address HIV/AIDS at more than 5,250 health facilities in more than 25 LMICs. Both ICAP and the MPP are partners in the OPTIMIZE Consortium, led by Wits RHI and supported through the United States Agency for International Development (USAID). OPTIMIZE is a global partnership unifying distinct voices to achieve a common goal: accelerating access to simpler, safer and more affordable HIV treatment.
In April 2016, the Medicines Patent Pool (MPP) and the TB Alliance signed a Memorandum of Understanding to encourage the development of new tuberculosis (TB) regimens and ensure their availability in low- and middle-income countries. The two organisations are working together on a range of initiatives with a focus on public health-oriented licensing strategies and the sharing of intellectual property to spur research and development of affordable new TB treatments.